Line of abiraterone acetate in castration‑resistant metastatic prostate cancer ‑ Does it matter? report of a multi‑institutional experience.

ABSTRACT

OBJECTIVE: We present our data comparing retrospectively the efficacy of abiraterone and cabazitaxel in patients who progress after docetaxel treatment. PATIENTS AND METHODS: The study included 56 patients diagnosed with hormone‑refractory metastatic prostate cancer who were previously treated with abiraterone therapy at four oncology centers in Turkey. RESULTS: With abiraterone, the patients had a median progression‑free survival (PFS) of 5.9 months (95% confidence interval (CI) for hazard ratio (HR) (4.4–7.4)) and an overall survival of 13.4 months (95% CI for HR (5.5–21.3)). When we compared the disease‑free survival (DFS) of reference patients treated with cabazitaxel as a second‑line treatment with those receiving second‑line abiraterone therapy, there was no significant difference. (PFS = 5.9 months with cabazitaxel vs. 6.7 months with abiraterone, P = 0.213). CONCLUSION: This study has shown that in our experience abiraterone acetate is an effective agent in metastatic castration‑resistant prostate cancer (mCRPC) regardless of the line of treatment.